Amarantus Announces Preclinical Development Timeline for MANF Therapeutic
SUNNYVALE, Calif., Apr 11, 2013 (BUSINESS WIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today provided a timeline of key activities and milestones related to the preclinical development of MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor). The Company is currently focused on developing MANF across three broad categories: Parkinson's disease and Traumatic Brain Injury; large systemic applications such as Ischemic Heart Disease and Diabetes; and orphan indications.
"We plan to move forward on a number of fronts this year with MANF, leading potentially to one or more Investigational New Drug (IND) filings in 2014," said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus. "The pace and scope of activities outlined today reflect the unique properties of MANF, the positive results reported earlier this year in neuroprotective and neurorestorative animal models of Parkinson's disease and supportive data from the published literature."
The upcoming activities related to Amarantus' Parkinson's disease program include:
-- Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
-- Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
-- Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
-- Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson's disease, and the Company's current patent positi